Lanthanum carbonate is a phosphate binder that is used to reduce serum phosphate levels in patients with end-stage renal disease (ESRD). Lanthanum forms insoluble lanthanum phosphate complexes that are supposed to pass through the gastrointestinal (GI) tract unabsorbed. Phosphate binders have been reported to deposit in the GI tract and can cause mucosal injury. There are few case reports of GI bleeding associated with phosphate binder deposits. This case report presents a patient with iron deficiency anaemia secondary to biopsy-proven lanthanum deposits in the upper GI tract. There were no overt signs of active GI bleeding. Patient's anaemia improved with discontinuation of the phosphate binder. Lanthanum could be a hidden cause of resistant anaemia among patients with ESRD through asymptomatic GI blood loss.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6424195 | PMC |
| http://dx.doi.org/10.1136/bcr-2018-226157 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Evaluation of self medication practices and prescription patterns in patients of chronic kidney disease: A cross-sectional, questionnaire based study.
Perspect Clin Res
August 2024
Department of Nephrology, Seth GS Medical College and KEM Hospital, Mumbai, Maharashtra, India.
Background: Pharmacotherapy of chronic kidney disease (CKD) consists of prescribing myriad of drugs such as antihypertensives, antidiabetics, and phosphate binders to delay disease progression and control the comorbidities, resulting in inherent variability in prescriptions. In addition, tendency to self-medicate may further aggravate the condition. Hence, the present study was planned to assess self-medication practices and variability in prescription patterns in CKD patients.
View Article and Find Full Text PDFCombination Oxylanthanum Carbonate and Tenapanor Lowers Urinary Phosphate Excretion in Rats.
Kidney360
January 2025
Unicycive Therapeutics, Los Altos, CA, United States.
Background: This study evaluated the combined effects of oxylanthanum carbonate (OLC), an investigational phosphate binder, and tenapanor, an approved sodium/hydrogen exchanger 3 (NHE3) inhibitor that reduces paracellular phosphate absorption, on urinary phosphate excretion in rats on a high phosphorus diet.
Methods: Sixty-four male Sprague Dawley rats were randomized into eight groups: vehicle; tenapanor (0.15 mg/kg) only; OLC (0.
Sevelamer-induced Gastrointestinal Mucosal Injury: A Critical Review for Clinicians.
J Community Hosp Intern Med Perspect
November 2024
Gastroenterology & Hepatology, St. Joseph's University Medical Center, Paterson, USA.
Sevelamer is a non-absorbable polymer used to treat hyperphosphatemia in individuals with end-stage renal disease (ESRD) undergoing hemodialysis. The deposition of sevelamer crystals in the gastrointestinal (GI) tract, especially in the colon, can cause mucosal inflammation, pseudopolyps, ulceration, ischemia, or necrosis. Owing to its rarity and lack of physician awareness, the actual incidence and prevalence of sevelamer-induced gastrointestinal mucosal injury (SIGMI) remain unknown.
View Article and Find Full Text PDFPhosphate binder in dialysis: a cross-sectional study of patients' adherence and pill burden.
J Bras Nefrol
January 2025
Universidade Nove de Julho, São Paulo, SP, Brazil.
Introduction: Phosphate (P) binders are among the most common medications prescribed to control P levels in patients with chronic kidney disease on dialysis. There is still a paucity of data on adherence to P binders with no comparison between dialysis modalities.
Methods: We accessed factors associated with P binder adherence among patients on dialysis in an academic hospital.
Tenapanor: A novel therapeutic agent for dialysis patients with hyperphosphatemia.
Ther Apher Dial
January 2025
Division of Nephrology, Endocrinology, and Metabolism, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Kanagawa, Japan.
Patients on dialysis often develop hyperphosphatemia, contributing to an increased risk of cardiovascular events and mortality. Currently, several types of phosphate binders (PBs) exist for the treatment of hyperphosphatemia, but they are sometimes associated with drug-specific side effects and high pill burden, making it difficult to control serum phosphorus appropriately. Tenapanor, which has a novel mechanism to reduce serum phosphorus via selective sodium/proton exchange transporter 3 inhibition, was approved for hyperphosphatemia in Japan in 2023.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!